STRS Ohio’s Carisma Therapeutics CARM Stock Holding History

STRS Ohio’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,795	Closed	-$57K	–	2067
2022 Q1	$57K	Hold	4,795	–	–	﹤0.01%	1926
2021 Q4	$78K	Hold	4,795	–	–	﹤0.01%	1939
2021 Q3	$76K	Buy	4,795 +2,820	+143%	+$135K	﹤0.01%	1990
2021 Q2	$182K	Buy	+1,975	New	+$126K	﹤0.01%	1840
2015 Q1	–	Sell	-85	Closed	-$18.6K	–	1811
2014 Q4	$20K	Hold	85	–	–	﹤0.01%	1687
2014 Q3	$19K	Buy	+85	New	+$20.2K	﹤0.01%	1742

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

STRS Ohio's CARM Position: Q2 2022 in Review

STRS Ohio sold out of Carisma Therapeutics (CARM) in Q2 2022, closing a stake of 4,795 shares — an estimated $57K sold.

STRS Ohio first reported a position in CARM in Q3 2014 and held it in 6 quarters. The position peaked at $182K in Q2 2021. 73 funds tracked by Wall St. Rank hold CARM as of Q2 2022.

STRS Ohio reported no remaining Carisma Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 4,795 Carisma Therapeutics shares in Q2 2022, an estimated $57K.
STRS Ohio first reported a position in Carisma Therapeutics in Q3 2014 and held it in 6 quarters.
STRS Ohio's Carisma Therapeutics position peaked at $182K in Q2 2021.
73 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.